BioN­Tech CEO in­ter­view: On boost­ers, the fu­ture of Covid-19, and the plan to make and ship the next vac­cine in 3 ...

4 years ago
People
Coronavirus

Covid-19 roundup: Ada­gio plans to sub­mit EUA by Q2 in 2022; HIPRA to en­ter PhII tri­als

4 years ago
Coronavirus

As Gink­go looks to clear its name, the feds have come sniff­ing around on the heels of short sell re­port

4 years ago
Pharma

Mer­ck looks to ditch the nee­dles with its next-gen oral PC­SK9 in­hibitor for high cho­les­terol

4 years ago
R&D

For­mer Blue­print vets take their new biotech out of stealth, with STAT3 in their sights

4 years ago
Financing
Startups

Me­di­da­ta So­lu­tions co-founder Glen de Vries dies in plane crash

4 years ago
People

Reel­ing from PD-1 slap­down, In­cyte stirs con­cerns with side ef­fects of oral PD-L1 — al­though drug is al­so 'clear­ly ...

4 years ago
R&D

Just the idea of Aduhelm's long-term fi­nan­cial risks has CMS jack­ing up pre­mi­ums, de­ductibles for 2022

4 years ago
Pharma
FDA+

‘It’s a trans­for­ma­tion’: Re­searchers are tak­ing Deep­Mind’s ground­break­ing pro­tein fold­ing soft­ware to places ...

4 years ago
Discovery
In Focus

Eli Lil­ly and Boehringer In­gel­heim set their sights on acute heart fail­ure with new Jar­diance da­ta

4 years ago
R&D

J&J looks to toss its SGLT2 hat in the ring for two types of heart fail­ure

4 years ago
R&D

J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

4 years ago
Weekly

A cou­ple months ahead of its PDU­FA date, Bris­tol My­ers rolls out long-term da­ta for mava­camten

4 years ago
R&D

Glax­o­SmithK­line’s Vi­iV Health­care aims to shift HIV dai­ly pill think­ing in first DTC ads

4 years ago
Pharma
Marketing

Ap­pil­i's Covid-19 oral an­tivi­ral fails PhI­II tri­al; On­col­o­gy biotech Ankyra rais­es $45M in Se­ries B

4 years ago
News Briefing

Spurned by FDA on an­oth­er im­munother­a­py, Agenus holds up ear­ly da­ta for CT­LA-4 drug across tu­mor types

4 years ago
R&D

As­traZeneca ex­pects 'mod­est prof­itabil­i­ty' for next round of Covid-19 vac­cine sup­ply deals — and prunes pipeline in ...

4 years ago
R&D
Pharma

It’s Califf: Biden picks the for­mer FDA com­mish to head back to the helm

4 years ago
People
FDA+

No­var­tis touts more late-stage da­ta for in­clisir­an, the once-cen­ter­piece heart drug spurned by the FDA

4 years ago
R&D

Cit­ing mi­graine drug growth and pan­dem­ic, Lund­beck to cut 300 jobs and close In­dia fa­cil­i­ty

4 years ago
Pharma

Cor­texyme low­ers dose amid safe­ty con­cerns, rais­ing ques­tions about fu­ture of off­beat Alzheimer’s ap­proach

4 years ago
R&D

J&J sets out to split the world's largest health­care con­glom­er­ate, hiv­ing off the con­sumer di­vi­sion

4 years ago
Deals

Cy­toIm­mune CEO breaks down her 3 'pil­lars' of suc­cess; For­mer No­var­tis, Gilead ex­ec Alessan­dro Ri­va to lead an ul­tra ...

4 years ago
Peer Review

Adap­ti­m­mune says it's (near­ly) ready to head to the FDA with TCR can­cer ther­a­py

4 years ago
R&D
First page Previous page 614615616617618619620 Next page Last page
A service from the Financial Times